This trial failed to show benefit with adjuvant mTOR inhibitor everolimus when added to endocrine therapy. There was a high discontinuation rate of everolimus due to side effects which likely played a role. I suspect if the the dosing regimen was weekly it would have been tolerable and show an improvement in the standard of care as seen in this previous study
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer